



Viertel Cancer
Research Centre

2025 – 2026 REPORT

About us

Cancer Council Queensland's Viertel Cancer Research Centre has been at the forefront of cancer research in Queensland for over 20 years, helping to prevent cancer, improve diagnoses and enhance care.

We are working towards a future that empowers Queenslanders to reduce their risk of cancer and support those affected by cancer.

Cancer Council Queensland acknowledges the Traditional Custodians of the different First Nations across Queensland.

We recognise the deep and enduring spiritual connections Aboriginal and Torres Strait Islander people have to Country, and honour the role that Country, community and culture has in sustaining health, hope and healing. Respecting this and working in partnership will improve cancer outcomes, reduce inequities, and support culturally safe, respectful and inclusive care.





Contents

- 2 Message from the CEO
- 3 Message from the Research Leads
- 5 Cancer in Queensland
- 6 Contributing to the global cancer research effort
- 7 Research highlights 2025-2026
- 8 Our priority research areas
- 14 Flagship projects
- 26 Cancer Council Queensland Extramural Grant Program
- 28 Our team
- 30 Appendices

Message from the CEO

Adjunct Associate Professor

Matt Gardiner

CHIEF EXECUTIVE OFFICER
CANCER COUNCIL QUEENSLAND

Research is a fundamental pillar of Cancer Council Queensland's mission, helping us better understand cancer, improve prevention and early detection, strengthen survivorship, and ultimately improve outcomes for Queenslanders and indeed, people around the world.

When I reflect on the achievements of the Viertel Cancer Research Centre over the past year, I find myself thinking less about publications, grants and projects, and more about the people behind them.

Behind every study, every dataset, every partnership and every discovery is a group of talented and dedicated individuals united by a shared purpose. Research is often a long game. Progress can take years rather than months and meaningful change rarely arrives in a straight line. It requires curiosity, discipline, patience, collaboration and resilience, coupled with a belief that today's work can create a better future for people we may never meet.

At Cancer Council Queensland, our approach reminds us that every statistic ultimately represents a person, a family and a community. It challenges us to look beyond cancer itself and better understand the contexts in which people live their lives. This perspective has shaped much of our research, from understanding inequities in outcomes and access to care, through to improving communication, survivorship and support. It reflects a simple but important belief: great research does not simply ask what works, but for whom, under what circumstances, and how we can ensure the benefits are shared as fairly as possible.

This is one of the strengths that makes Cancer Council Queensland's research contribution unique. While we maintain the highest standards of scientific rigour, our position as an independent charity allows us to pursue questions that might otherwise struggle to find a home. We can respond to the needs of communities, learn from lived experience and invest in research that is not only academically important, but practically meaningful. Our focus is not simply on generating knowledge. It is on ensuring that knowledge contributes to better services, stronger systems and healthier communities.

What gives me the greatest confidence for the future is not any single project or finding. It is the capability, integrity and dedication of the people leading this work. At a time when there are many competing voices for attention, our researchers remain focused on what matters most: rigorous evidence, meaningful collaboration and improving the lives of Queenslanders affected by cancer. Their commitment to that purpose continues to strengthen both our organisation and the communities we serve.

Across Cancer Council Queensland, we are continuing to strengthen our capability, systems and leadership to support the impact we seek to create. Research has long been one of our organisation's greatest strengths and I am excited by the opportunities ahead to further connect research, service delivery, prevention, advocacy and community engagement. This creates new opportunities for evidence to move beyond discovery and into action, translating knowledge into meaningful change for Queenslanders affected by cancer.



This work is made possible through the confidence and generosity of many supporters. We remain deeply grateful to the Sylvia and Charles Viertel Charitable Foundation for its enduring commitment to cancer research in Queensland. We are equally thankful to the many individuals, families, trusts, foundations and supporters who invest in the possibility of a better future through research. Whether through a major gift, a philanthropic partnership or a regular donation, every contribution helps create opportunities for discovery, innovation and impact.

As we look to the year ahead, I am filled with hope.

Hope in the capability of our researchers. Hope in the strength of our partnerships. Hope in our growing ability to connect research, practice, advocacy and community action in ways that create lasting change. Most importantly, hope in the possibility that the knowledge we generate today will contribute to a future where fewer Queenslanders experience cancer, more Queenslanders live well after a diagnosis and every person has the opportunity to benefit from advances in research.

There remains much to do, but there has never been a more important time to ask bold questions, pursue meaningful answers and ensure that research continues to serve the people and communities at the centre of our mission.

Message from the Research Leads

Professor Louisa Collins

RESEARCH LEAD, CANCER PREVENTION AND SURVIVORSHIP

Professor Peter Baade

RESEARCH LEAD, CANCER EPIDEMIOLOGY

Through this report, we are pleased to share the achievements of our research team over the past year and the impact they have had. The work covers six priority areas: **cancer prevention and early detection, survivorship, understanding disparities, childhood cancer, economics and communication**. These achievements recognise that our research not only advances knowledge but delivers real-world improvements in care, policy and outcomes for all Queenslanders affected by cancer.

Among our highlights:

- To help us to continue to deliver impact through our research, our teams were successful in securing over **\$1 million in new funding** in an increasingly competitive funding environment.
- **Deeper engagement** with other community organisations, such as Hepatitis Queensland for the *Viral Hepatitis and Liver Cancer – Queensland Report*, brought together community-embedded expertise and population-level data to inform policy and service design discussions.
- We provided **evidence to help shape national cancer initiatives**, including the National Cancer Data Framework (via the Australian Cancer Atlas and the Australian Childhood Cancer Registry), the Melanoma Screening Roadmap (through data linkage and reanalysis of long-standing research cohorts), and Tobacco and E-cigarette Control policy (through health economic analysis).

- We are investing in the **next generation of researchers** – externally through the 2026 Next Generation Cancer Research Fellowship scheme and internally by supporting 5 staff members to complete their PhDs and supervising 48 postgraduate researchers through their training.
- Our research was published in **55 peer-reviewed papers** this year, shaping conversations well beyond our own walls. It was also reported through **99 presentations at national and international conferences**, including several invited and plenary addresses helping inform thinking and practice across the field.

Our partnerships with universities, health services and community organisations remain central to how we work, keeping our research grounded, far-reaching and connected to the people it's meant to serve.

None of this would be possible without our researchers' dedication, the generosity of our supporters and the willingness of those with lived experience to help shape what we study and how. Thank you to everyone who contributed to this.

Looking ahead, we'll keep working toward research that reaches and empowers communities, shapes systems and leads to better cancer outcomes for all Queenslanders.





Cancer in Queensland

More than
321,382

Queenslanders are alive today
after a cancer diagnosis in the
last 30 years (1994-2023)

10,797

Queenslanders died of
cancer in 2023.

1 in 3

cancers can be prevented
by making healthy lifestyle choices.

37,255

Queenslanders were diagnosed
with cancer in 2023.

1 in 2

Queenslanders will be diagnosed
with cancer **by the age of 85.**

The **five most common
cancers** in Queensland are
prostate, melanoma, breast,
colorectal and lung cancer.

Queensland's five-year cancer
survival rate has increased from

53% to 74%

from the 1980s to 2023.

Based on current trends
and predicted population
changes, approximately

43,000

Queenslanders are expected
to be diagnosed with
cancer in the year **2028.**

Data source: Queensland Cancer Register, 2025 Cancer Council Queensland Data extract, 1982-2023 (latest data available at time of publishing)

Contributing to the global cancer research effort

2004 – 2026

887

Scientific publications with a total citation count over **58,803**

34.8%

of publications involve international collaboration

62.7%

of publications involve national collaboration

265

publications in the **top 10%** most cited publications worldwide (field-weighted)

(Source: SciVal, August 2026)

1 July 2025 – 30 June 2026

26

grants and consultancies awarded/collaborated on

99

presentations at national and international conferences

55

scientific articles published on our research findings (84% in top-ranked journals)

Supporting **5** staff members to complete their PhDs

Supervising **45** postgraduate researchers through their training

Research highlights 2025-2026

We collaborated with Hepatitis Queensland to deliver the **Viral Hepatitis and Liver Cancer – Queensland Report**, highlighting the state's progress in preventing liver cancer and improving outcomes for people with hepatitis B and hepatitis C. The report offered critical evidence to guide coordinated, equity-focused action to:

- strengthen prevention, early detection and culturally safe care
- reduce avoidable deaths
- improve health outcomes across Queensland

We continued to manage and expand the **Australian Childhood Cancer Registry**, growing the nation's only population-based childhood cancer registry to more than 26,350 records of children diagnosed with cancer since 1983.

We expanded the **Australian Cancer Atlas** to include new visual explainers that enhance public engagement and translate complex statistics into accessible and compelling stories.

Our researchers continued to play a key role in the national, three-year program of work to develop a roadmap for a **targeted melanoma screening program** in Australia.

We actively developed and supported the **next generation of cancer researchers** across a diverse range of fields, including:

- epidemiology
- advanced modelling
- childhood cancer nutrition
- cancer prevention through healthy lifestyle behaviours
- health services research
- rural and remote cancer care
- exercise oncology

We secured **NHMRC Partnership Project** funding to undertake a collaborative research program with Cancer Council Australia, Lung Foundation Australia and Heart Foundation Australia to evaluate the impact of Australia's vaping reforms on vaping-related harms and costs.



Cancer prevention & early detection

PRIORITY RESEARCH AREA

Up to 40% of cancers are preventable through healthy lifestyle changes. However, behaviour change is complex and influenced by a range of social, cultural and environmental factors.

Cancer screening remains one of the most effective strategies for early detection and reducing cancer-related deaths. Yet, participation in national programs remains low – particularly among priority populations, including those living in rural and remote areas.

Our research seeks to address these disparities by developing culturally appropriate, community-driven solutions that promote equitable access to screening and prevention.

Ultimately our goal is to:

- Prevent cancer.
- Detect cancer early.
- Reduce disease burden.
- Keep people out of hospitals and off waiting lists.

Flagship Projects

- **BestBowel – Increasing participation in the National Bowel Cancer Screening Program**
- Cancer-Free Cultures (ECCQ)
- MST-25 – Melanoma Screening Trial 25-year follow-up of survival, skin cancer healthcare use and costs
- LUMINAS – Long-term melanoma outcomes and health service utilisation examined through national data linkage and advanced statistical analyses





FLAGSHIP PROJECT

BestBowel

Why is this project important?

BestBowel targets one of Australia's most preventable cancer deaths: bowel cancer. Currently the second leading cause of cancer-related death in Australia, bowel cancer is highly treatable in up to 99% of cases, when caught early. This project seeks to address critically low screening participation levels – currently around 40% – which limit the life-saving potential of the National Bowel Cancer Screening Program. BestBowel delivers significant population-level impact, with modelling showing that raising participation to 60% could prevent more than 80,000 bowel cancer deaths over the next 20 years.

What has been achieved in 2025-2026?

- A key achievement was the progression of advanced evidence-based screening communication. Cancer Council Queensland's A/Professor Belinda Goodwin led research into redesigning the National Bowel Cancer Screening Program's mailed invitation letter, drawing on health psychology and consumer insights.

- In collaboration with the National Bowel Cancer Screening Program and national research collaborative, the Bowel Cancer Screening Alliance, we delivered a redesigned national invitation letter. Featuring simplified design, visibility prompts to address procrastination and clearer test kit instructions to boost confidence and accessibility, this new letter rolled out to eligible Australians from August 2025.

What is next?

We will test the letter modifications under gold-standard, randomised controlled trial conditions to rigorously evaluate the impact on screening kit return rates. The BestBowel project will also expand its research focus to the newly eligible 45–49 age group, understanding the factors that drive and deter their screening participation to inform tailored, effective intervention strategies.



Cancer survivorship

PRIORITY RESEARCH AREA

A cancer diagnosis can impact every aspect of life, including physical, emotional, social and financial wellbeing.

Our research aims to understand the experiences and support needs of people diagnosed with cancer, as well as those of their families and support networks. We identify gaps in services then collaborate with communities and providers to design and evaluate supportive care solutions to improve health outcomes.

Flagship Projects

- **UNIQUE**
- **Social connection among women impacted by cancer**
- ACTIVATE Program
- Cancer Council Australia (CCA) Navigation Program
- ECORRA - Equitable Cancer Outcomes across Rural and Remote Australia
- Implementing diet, exercise and lifestyle support into community cancer care
- Living systematic review and network meta-analysis of the effectiveness of exercise and diet interventions on survival outcomes in cancer
- Supporting Nutrition in Among Childhood Cancer Survivors (SNACCS)
- Securing equitable access to safe and nutritious food in cancer (SURECAN)
- Travelling for Treatment (T4T)



FLAGSHIP PROJECT

UNIQUE

Why is this project important?

UNIQUE recognises the diversity of support needs and lived experiences among Queenslanders impacted by cancer. Through inviting people to complete a co-designed, qualitative questionnaire about their needs and experiences post-diagnosis, UNIQUE aims to better understand how cancer impacts the lives of Queenslanders, provide insights for accessible service design and delivery, and connect Queenslanders to information, support and research opportunities.

UNIQUE aims to:

- Address the growing needs of cancer survivors and carers, as more Queenslanders are diagnosed and live with the long-term impacts of cancer.
- Improve equity and access to supportive care, ensuring services are relevant, accessible and aligned with real-world needs.
- Inform service improvement and innovation, helping ensure no Queenslanders navigate cancer alone.

What has been achieved in 2025-2026?

- We piloted UNIQUE in partnership with the Queensland Cancer Registry at Cancer Alliance Queensland.
- From July-December 2025, 422 people participated in UNIQUE. This group was diverse across age, gender, remoteness, ethnicity, cancer type and months post-diagnosis.
- As part of the pilot, we tested different options for consent processes, questionnaire design and completion methods. We identified that implied consent processes, a semi-structured questionnaire design with guided prompts, and offering online, paper and phone options for questionnaire completion were most effective.
- When given the option, 60% opted in to be contacted about further research opportunities and 50% opted in to receive information about available support. Providing these options streamlines access to research opportunities for people with cancer and optimises the cost-benefit of registry-based recruitment. It also highlights how research participation can offer reciprocal benefits by linking participants to available support services.

What is next?

We will test and validate AI-assisted methods for analysing the large volumes of qualitative data collected in UNIQUE. This work will enable us to identify the feasibility of large-scale implementation of UNIQUE to create a live database of the support needs and experiences of Queenslanders affected by cancer. It will also assist us to uplift needs and experiences among priority populations and track changes over time.

Through Cancer Council Queensland's networks and partners, we will extend UNIQUE to include family members and friends who provide support to a loved one with cancer. Additionally, we will work with multicultural groups to adapt UNIQUE so that it is relevant and accessible for people from culturally and linguistically diverse backgrounds.



FLAGSHIP PROJECT

Social connection among women impacted by cancer

Why is this project important?

Women affected by cancer, including those who care for a loved one with cancer, often have unmet emotional and social support needs. These women also face unique challenges, including changes to their health, identity, relationships and everyday roles. These experiences shape their preferences for social connection and care.

This project aims to explore how peer support groups impact social and mental health for women affected by cancer, including carers, and to better understand how to create groups that are useful, acceptable and accessible. It will provide practical guidance to address the unmet peer support needs of these women, advancing person-centred care across Queensland and beyond. This research has also informed Women's Connect, a state-wide peer support group for women impacted by cancer, delivered by Cancer Council Queensland.

What has been achieved in 2025-2026?

- We conducted 12 focus groups exploring the needs of, and preferences for, peer support groups for women affected by cancer. These focus groups involved 40 people, including healthcare professionals and women diagnosed with cancer or caring for a family member or friend with cancer.
- We identified that peer support groups for women should be accessible, peer-driven, continuous, open, safe, holistic, led by skilled and experience facilitators, flexible, offered in multiple delivery modes and supported by professionals.
- We reviewed previous research on peer support groups for people affected by cancer. We found 121 peer-reviewed studies describing peer support groups for people with cancer and/or caring for someone with cancer. Most research to date has focused on people with cancer, with few studies specific to carers, highlighting the need for greater attention to this group.

What is next?

We will combine the focus group findings with input from women with lived experience and healthcare professionals to develop a set of key principles to guide the development of future peer support groups for women affected by cancer. These principles can help improve the acceptability, engagement and equity of peer support groups for this cohort.

From our review of previous research, we will explore how effective peer support groups are at improving the health and wellbeing of women impacted by cancer, including the most improved outcomes and most effective peer support groups type. Separate reviews will be conducted for people with cancer and those caring for someone with cancer to provide a deeper understanding of how these groups can best support women with distinct experiences and challenges.



Understanding cancer disparities

PRIORITY RESEARCH AREA

While overall cancer outcomes have improved, these gains have not been experienced equally across all communities. Our research aims to identify and address disparity in cancer outcomes through targeted research and data-driven initiatives.

We investigate geographic and social factors that influence cancer screening, diagnosis, treatment and survival and analyse variations in these cancer outcomes. This allows us to generate evidence to inform targeted and effective interventions and support initiatives that promote equity in cancer care delivery.

We lead efforts to translate data into action by:

- Providing insights to inform local and national cancer policy.
- Supporting data-driven planning for health services and resource allocation.
- Advocating for equitable access to cancer prevention, diagnosis and treatment for all Australians.

Flagship Projects

- **Australian Cancer Atlas 2.0**
- **Understanding and Addressing Prostate Cancer Disparities in Rural and Remote Communities: A Multi-faceted Approach (UNDERSTAND-RARC)**
- Cancer epidemiology cohorts – assessing predictors of long-term survival
- Generating cancer outcome estimates for alternative geographical classifications





FLAGSHIP PROJECT

Australian Cancer Atlas 2.0

Why is this project important?

The Australian Cancer Atlas reveals inequities in cancer outcomes, enabling a clear understanding of where cancer burden and disparities are greatest across Australia. It supports evidence-based policy and practice change, helping drive prevention, earlier diagnosis and improved cancer management. The unique national resource empowers policymakers, health services, researchers and communities to act on place-based cancer evidence.

What has been achieved in 2025-2026?

- Our data analysis found that every year, nearly 3,400 cancer-related deaths in Australia were attributable to spatial disparities in survival, comprising 12% of all cancer-related deaths. In remote areas, 30% of cancer-related deaths were attributable to spatial disparities in survival. These results reached a broad audience after they were published in the Medical Journal of Australia and presented at national conferences for epidemiology and remote health.

- We have completed spatial modelling for updating the diagnosis and survival estimates in the Australian Cancer Atlas, using the most current data available from the Australian Institute of Health and Welfare (2012-2021). Modelling of trends over time is nearly complete and will also be incorporated into the Atlas.

What is next?

Funding from Cancer Australia will enable further updates for the cancer risk factor as well as testing and screening measures in the coming year

We will conduct spatial modelling of early-onset cancers – those diagnosed among people aged 20 to 49 years – to understand if spatial differences can provide insights into differences in the aetiologies of these increasingly prevalent cancers. Models will also be fitted to a comparison age group (50+ years).

We will continue to add new treatment and diagnostic indicators to the Atlas, using linked data accessed through the National Health Data Hub.



FLAGSHIP PROJECT

UNDERSTAND-RARC

Why is this project important?

UNDERSTAND-RARC addresses a clear and persistent health inequity, with rural and remote men experiencing higher rates of advanced disease and prostate cancer mortality. This project provides actionable evidence to inform targeted interventions, service planning and policy responses to improve access to prostate cancer care. It also supports equitable cancer outcomes, enabling organisations and health services to reduce disparities and improve survival for men regardless of where they live.

What has been achieved in 2025-2026?

- We generated evidence on area-level characteristics associated with poorer prostate cancer survival, supporting the identification of priority areas for further investigation.
- Our research team translated prostate cancer survival findings into academic and policy-facing outputs, including a peer-reviewed manuscript submission and an international conference presentation. We also presented our findings to Cancer Australia, the Australian Institute for Health and Welfare and the Department of Health, Disability and Ageing.
- Quantitative findings were used to inform the design of a follow-up qualitative study.
- Our work identified area-level factors associated with spatial variation in prostate cancer incidence, contributing to a broader evidence base on geographic inequities in prostate cancer outcomes.

What is next?

We will continue to collect and analyse qualitative data through interviews and focus groups. Additionally, we will analyse information and commentary mined from social media to better understand the topics discussed in online forums by men with prostate cancer and the sentiments of those discussions. A key future focus is to plan similar studies centred around other types of cancers.

Childhood cancer

PRIORITY RESEARCH AREA

Cancer Council Queensland's research into childhood cancer is centred on maintaining and expanding the Australian Childhood Cancer Registry, a national databank with over 26,350 records of every child diagnosed with cancer in Australia since 1983.

The Registry enables population-based research and long-term follow-up studies essential for improving outcomes for children affected by cancer.

Our research explores the long-term health impacts of childhood cancer, addresses key gaps in survivorship and generates locally relevant evidence through analysis of Registry data.

Through these efforts we aim to:

- Advance clinical knowledge using population-level data.
- Inform service delivery and care models tailored to the needs of childhood cancer survivors.
- Guide policy to improve long-term health outcomes.
- Support families by identifying key resource needs.

Flagship Projects

- **Australian Childhood Cancer Registry**
- **Research Priorities for Childhood Cancer**
- Late effects of childhood cancer (LACE)





FLAGSHIP PROJECT

Australian Childhood Cancer Registry

Why is this project important?

The Australian Childhood Cancer Registry provides a national evidence base essential for reporting, international benchmarking and childhood cancer research. Importantly, it improves outcomes for children with cancer by ensuring clinicians, researchers and policymakers have access to accurate, reliable data. Our work supports long-term planning and investment by informing policy decisions and future service needs for childhood cancer care in Australia.

What has been achieved in 2025-2026?

- The Advisory Group for the Registry was re-established to engaged with key stakeholders across all jurisdictions including clinician, First Nations and consumer representations.
- We collated data for all children diagnosed in Australia between 1983 and 2022 in a report to Cancer Australia: Strengthening Childhood Cancer Data. The report details incidence, staging, prognostic indicators, mortality and survival statistics for 15 different types of childhood cancer. These are reported by remoteness and area-based socio-economic status.

- A new dashboard for reporting childhood cancer statistics was developed.

What is next?

Recommendations funded by Cancer Australia for action include:

1. Sustaining the Registry's core activities.
2. Updating and expanding key variables collected by the Registry including broadening the age range to include adolescents up to 19 years, reviewing prognostic indicators and incorporating equity measures.
3. Exploring and addressing gaps in data completeness.



FLAGSHIP PROJECT

Australian Child & Adolescent Cancer Research Priority Setting Partnership (PSP)

Why is this project important?

The Australian Child and Adolescent Cancer Priority Setting Partnership (PSP) provides an evidence-based roadmap to shape the future research agenda in child and adolescent cancer care. It ensures future research is driven by lived experience – addressing a critical gap where patient, survivor and family perspectives are often underrepresented – and guides funders, researchers and policymakers toward the most important and unanswered questions.

The PSP will strengthen relevance and trust in cancer research, aligning national research efforts with real-world needs across the entire cancer journey, from diagnosis to survivorship or bereavement. It is also recognised by Cancer Australia in its Child, Adolescent and Young Adult Cancer Roadmap as a critical strategy for engaging with consumers to establish research priorities.

What has been achieved in 2025-2026?

The PSP released the Australian Research Priorities for Child and Adolescent Cancer report in February 2026. It identified the top 10 research priorities in child and adolescent cancer and made recommendations for researchers, research funders, policy makers and charities.

What is next?

The project's goals are to ensure the identified priorities guide future research investment and drive meaningful, long-term change in childhood and adolescent cancer outcomes in Australia. Report recommendations include:

- Share the priorities with major research funders to guide future investment.

- Provide the priorities to cancer organisations and research networks to support coordinated research efforts.
- Disseminate the findings across clinical and academic communities to inform practice and future studies.
- Present the priorities to government and policy partners to influence national planning and funding decisions.

**The PSP was led by Cancer Council Queensland's Dr Natalie Bradford, funded by Queensland University of Technology and delivered in partnership with the James Lind Alliance.*

Cancer economics

PRIORITY RESEARCH AREA

Cancer economics research focuses on identifying cost-saving, efficient and equitable approaches to cancer care. It builds the evidence base for investment in prevention, early detection, survivorship services, models of care and targeted interventions.

Cancer places a significant financial burden on patients, families, workplaces and health systems.

Our research aims to:

- Understand the economic impact of cancer.
- Evaluate which interventions provide the best value for money.

Embedded across other research priority areas, our health economics work contributes by:

- Informing service delivery.
- Guiding effective allocation of resources.

Flagship Projects

- **E4 Study – Evaluating health economic and equity consequences of government regulations of e-cigarette use**
- Roadmap for a National Targeted Melanoma Screening Program – Economic evaluation and modelling
- Labour productivity costs of cancer-related premature mortality in Australia
- Cost-effectiveness of PROCESS: Pancreatic cancer Relatives Counselling and Education Support Service trial.



FLAGSHIP PROJECT

E4 Study

Why is this project important?

E-cigarette use has increased rapidly, especially among young people, with concerns about nicotine addiction and other health harms. The E4 Study acknowledges that major reforms – including pharmacy-only access to e-cigarettes from 1 October 2024 – need evaluation, so decision-makers understand the likely impacts versus the counterfactual. Until now, there has been no comprehensive Australian modelling of the health and economic impacts of different regulatory options, especially for socio-economic equity impacts.

What has been achieved in 2025-2026?

- During the first year of the project, substantial progress was made across stakeholder engagement, governance, data acquisition, and model development.
- Conducted six meetings with stakeholders and project partners to inform and guide project activities.
- Developed a detailed study protocol and obtained ethics approval from the Metro

South Human Research Ethics Committee.

- Convened a stakeholder workshop attended by 25 participants to share project updates, discuss priorities and gather input to inform subsequent project activities.
- Delivered an oral presentation on the project's aims and planned approach at the Preventive Health Conference in Hobart in May 2026.
- Constructed a comprehensive mathematical model and started to populate the model using the best available evidence and data inputs.
- Started the model calibration to ensure outputs accurately reflect real-world conditions and outcomes.
- Applied to the Queensland Ambulance Service to access novel data on vaping-related ambulance callouts and injuries and received ethics approval.

What is next?

Over the next year, we will hold two additional stakeholder workshops, finalise the model inputs and analyses, produce the final modelling results and begin disseminating findings to stakeholders, policymakers and academic audiences.



Inform and communicate

PRIORITY RESEARCH AREA

Cancer Council Queensland is a primary source of information about cancer, including statistical information such as cancer diagnosis and survival rates; information about cancer risk behaviours, prevention and screening; and information about support when it's needed.


To ensure this information is impactful, it must be communicated in ways that are clear, accessible and easily understood. The growing use of advanced data analytics, digital storytelling and visualisation techniques offers powerful tools for engaging diverse audiences and supporting a range of communication goals.

Cancer Council Queensland plays a critical role in transforming complex cancer data into meaningful insights and actions, including:

- Using advanced analytics to identify trends and generate insights into cancer outcomes.
- Presenting complex data through engaging digital storytelling and visualisation.
- Supporting evidence-based decisions for individuals, communities and health systems.
- Tailoring communication to reduce disparities and reach priority populations.
- Promoting public awareness and policy advocacy to improve cancer outcomes.

Flagship Projects

- **Communicating cancer statistics using online tools**
- Communicating cancer burden through visual explainers
- CaRDO (Cancer Registry Data Online)
- Collaboration with Hepatitis Queensland on the *Viral Hepatitis and Liver Cancer – Queensland Report*





FLAGSHIP PROJECT

Online Dashboard Development, including visual explainers

Why is this project important?

Better cancer outcomes can be supported by ensuring policies and actions are informed by the best available, population-level cancer evidence. Our Online Dashboard Development project translates data into impact by making critical cancer statistics accessible to clinicians, policymakers and the public. It also drives awareness and change through trusted, routine reporting that underpins behavioural and policy decisions across Queensland and beyond.

What has been achieved in 2025-2026?

- Strengthened digital reporting platforms, including the full redevelopment of the Australian Childhood Cancer Statistics Online dashboard and the launch of CaRDO, enabling wider publication of cancer statistics without specialist expertise.
- Expanded evidence-based communication, through new visual explainers – including melanoma, liver cancer and data smoothing – developed with leading research partners as part of the Australian Cancer Atlas.

- Delivered targeted awareness initiatives, notably the Viral Hepatitis and Liver Cancer: Queensland Evidence Report in collaboration with Hepatitis Queensland.

What is next?

We will continue to lead the ongoing enhancement of core reporting systems to maintain timely, reliable access to Queensland cancer statistics. Additional visual explainers on leukaemia, myeloproliferative neoplasms and lung cancer will be developed to expand the suite of resources supporting the Australian Cancer Atlas. Additionally, we will develop new dissemination tools for policy relevance, enabling cancer statistics to be aggregated by other geographical regions such as Primary Health Networks and Electoral Districts to inform decision-makers at all levels.

Investing in better cancer outcomes

Cancer Council Queensland's Extramural Grant Program is a key component of our commitment to reducing the impact of cancer through funding external research, innovation and evidence-based care. By investing across the cancer research continuum – from discovery and translation to clinical implementation – the program strengthens Queensland's cancer research capability, supports the development of future research leaders and expands access to industry-independent cancer clinical trials. The program comprises three complementary funding initiatives that collectively contribute to better prevention, detection, treatment and survivorship outcomes.

Cancer Clinical Trials Support Scheme

The Cancer Clinical Trials Support Scheme (CCTSS) is a long-standing partnership between Cancer Council Queensland and the Queensland Government to increase opportunities for Queenslanders with cancer to participate in industry-independent clinical trials.

Rather than funding individual trials, the scheme supports the specialised workforce required to deliver them effectively. Through grants to hospitals and cancer treatment facilities, the scheme provides salary support for clinical trial data managers who play a critical role in patient screening and recruitment, trial coordination, data collection, regulatory compliance and trial administration.

Since its establishment, the scheme has contributed to substantial growth in clinical trial activity across Queensland and continues to strengthen research infrastructure and patient access to innovative treatments. The current partnership with Queensland Health represents an investment of almost \$8 million through to 2030. Cancer Council Queensland will contribute a minimum of \$2,625,000, including \$427,196 in 2025/26.

Lasting Impact

Together, the Extramural Grant Program's funding schemes help build a stronger and more connected cancer research ecosystem in Queensland. By supporting collaborative research, developing future research leaders and expanding access to industry-independent clinical trials, Cancer Council Queensland continues to invest in research that delivers meaningful benefits for patients, communities and the future of cancer treatment and control.

Accelerating Collaborative Cancer Research (ACCR) Grants

Established in 2019, the ACCR Grants scheme supported large-scale, multidisciplinary research programs that addressed priority areas of need, while building sustainable cancer research capacity in Queensland. The scheme aimed to accelerate the translation of research findings into improved patient outcomes, clinical practice and health policy, while fostering collaboration across institutions and disciplines.

Each grant provided \$500,000 per year over four years, co-funded through partnerships with participating research institutions. In 2025/26, Cancer Council Queensland contributed \$525,000. While no new Grants are being awarded, the scheme's legacy continues through the collaborative networks, research capability and translational outcomes it helped establish.

Next Generation Cancer Research Fellowships

Launched in 2023, the Next Generation Cancer Research Fellowships represent a new era of research investment. Delivered in partnership with the National Health and Medical Research Council (NHMRC), the fellowships support outstanding early-career researchers who are advancing innovation across the cancer continuum, from prevention and early detection to treatment and survivorship. Six fellowships were supported by Cancer Council Queensland in 2025/26, each providing up to \$150,000 to support both researcher salary and direct research costs. By investing in emerging leaders, the scheme promotes a strong and sustainable cancer research workforce and helps ensure a strong pipeline of future cancer research expertise for Queensland's future.



Our team

RESEARCH LEADS

Professor Peter Baade

Research Lead
Cancer Epidemiology

Professor Louisa Collins

Research Lead
Cancer Prevention and Survivorship

GROUP LEADS

- Associate Professor Belinda Goodwin
Group Lead, Cancer Prevention and Early Detection
- Dr Elizabeth (Lizzy) Johnston
Group Lead, Cancer Survivorship
- Associate Professor Rosa Spence
Group Lead, Cancer Survivorship
- Dr Jessica Cameron
Group Lead, Understanding Cancer Disparities
- Professor Natalie Bradford
Group Lead, Childhood Cancer
- Dr Daniel Lindsay
Group Lead, Cancer Economics
- Dr James Retell
Group Lead, Inform and Communicate

OPERATIONS

- Dr Sabine Fletcher
- Leanne Keeley
Senior Manager, Cancer Research Centre
- Suzy McLucas

RESEARCH STAFF

- Dr David Abernethy
- Dr Susannah Ayre
- Dr Charlotte Bainomugisa
- Brooke Baker
- Dr Kate Bolam
- Grant Brown
- Xanthia Bourdaniotis
- Sophia Cicchini
- Melissa Creed
- Anne Currell
- Dr Paramita Dasgupta

- Dr Anna Finnane
- Sean Francis
- Hayley Fung
- Associate Professor Belinda Goodwin
- Dr Ureni Halahakone
- Charly McIntyre
- Dr Muhammad Haroon
- Dr Kou Kou
- Katie Jorss
- Pamo Lozang
- Charly McIntyre
- Rachael Madders
- Jason Martin
- Dr Louise Marquart-Wilson
- Laura Newey
- Dr Quang Nguyen
- Leisa O'Neill
- Ana Pasarotti
- Emma Pearse
- James Rene
- Sheree Rye
- Dr Aminath Shausan
- Alyssa Taglieri-Sclocchi
- Dr Jeya Thurai
- Jazmin Vicario
- Bianca Viljoen
- Dr Joy Wang
- Leah Zajdlewicz

VISITING RESEARCHERS

- Hasan Alradhi | Integraal
Kankercentrum Nederland (IKNL)
- Dr Melanie Plinsinga | Griffith University
- Laurelie Wishart | Griffith University
- Shera Subba | Queensland University of Technology

DOCTORAL STUDENTS

- Xanthia Bourdaniotis (PhD, Psychology & Counselling) | The University of Queensland
- Caitlin Briggs (PhD, Psychology) | Queensland University of Technology
- Katelyn Collins (PhD, Health Psychology) | University of Southern Queensland
- Nathalia Fernando (PhD, Health Psychology) | University of Southern Queensland
- Hayley Fung (PhD, Health Science) | Flinders University
- Gill Gurkeerat (PhD, Epidemiology) | Griffith University
- Ming Ho (PhD, Health Economics) | The University of Queensland
- Sharif Islam (PhD, Statistics) | The University of Queensland
- Sandra Jensen (PhD, Lymphoedema) | University of Copenhagen, Denmark
- Haileyesus Legese (PhD, Epidemiology) | The University of Queensland
- Megumi Lim (PhD, Health Economics) | Queensland University of Technology
- Lawrence Lu (PhD, Health Science) | University of Queensland
- Mildred (Mmmbone) Lumwamu (PhD, Statistics) | Queensland University of Technology
- Jason Martin (PhD, Exercise Physiology) | Queensland University of Technology
- Doreen Nabulaku (PhD, Health Economics) | University of Sunshine Coast
- Nicole Perry (PhD, Health Science) | University of Southern Queensland
- Thi Hahn Phung (PhD, Health Science) | Queensland University of Technology
- Hildegard Reul-Hirche (PhD, Health Science) | Griffith University
- Alice Rogers (PhD, Nutrition and Dietetics) | Queensland University of Technology

- Melanie Rolfe (PhD, Health Science) | Queensland University of Technology
- Henriette Ryding (PhD, Nutrition and Dietetics) | Griffith University
- Camila Sanchez Saez (PhD, Survivorship) | Griffith University
- Leticia Watanabe Ribeiro (PhD, Public Health) | The University of Queensland

MASTERS STUDENTS

- Amala Benoy Epidemiology) | The University of Queensland
- Shannon Doyle (Biostatistics) | The University of Queensland
- Qi Fu (Public Health) | The University of Queensland
- Emily Jacobs Public Health) | The University of Queensland
- Emily Korn (Epidemiology) | The University of Queensland
- Christopher Lam (Biostatistics) | The University of Queensland
- Rhedyn Langley (Public Health) | Queensland University of Technology
- Siwan Li (Biostatistics) | The University of Queensland
- Colleen Pit (Health Sciences) | Queensland University of Technology
- Kiana Ronagh (Public Health) | The University of Queensland
- Shilpa Sivados (Public Health) | The University of Queensland
- Ivon Solano (Health Sciences) | The University of Queensland
- Shera Subba (Public Health) | Queensland University of Technology
- Hanruo Zhang (Epidemiology) | The University of Queensland
- Jingyu Zhao (Epidemiology) | The University of Queensland

HONOURS AND PLACEMENT STUDENTS

- Ambika Aul (Public Health, Honours) | The University of Queensland
- Charlie Brown (Psychology, Honours) | University of Southern Queensland
- Kelly Dorman (Psychology) | University of Southern Queensland
- Joanne Farrell (Psychology) | University of Southern Queensland
- Jeanie Loughlin (Psychology, Honours) | University of Southern Queensland
- Shelley Norris (Psychology, Honours) | University of Southern Queensland
- Tom O'Rielly (Nutrition and Dietetics, Honours) | Queensland University of Technology
- Jessica Singh (Nutrition and Dietetics) | Queensland University of Technology
- Theresa Stewart (Nutrition and Dietetics, Honours) | Queensland University of Technology
- Madeline Vela (Nutrition and Dietetics) | Queensland University of Technology
- Jodie Minniecon (Public Health) | Queensland University of Technology
- Shelley Norris (Psychology, Honours) | University of Southern Queensland
- Rebecca Reid (Nutrition & Dietetics) | Queensland University of Technology
- Emily van Wyk (Health Science) | The University of Queensland
- India Walsh (Health Science) | The University of Queensland

VOLUNTEERS/INTERNSHIPS

- Katie Jorss (Nutrition and Public Health)

Appendices

Appendix A: Awards

USQ Virtual Three Minute Thesis (3MT) – Runner Up

Awarded to Dr Katelyn Collins for presentation titled “*Dear You, Please Poo*”, relating to PhD research, September 2025, Virtual.

Best Presentation

Awarded to Dr Susannah Ayre for the “*Cancer Treatment, Survival, and Subsequent Diagnoses*” session at the 5th Cancer Council / AEA ECR Cancer Epidemiology Conference, November 2025, Virtual.

Best Presentation

Awarded to Dr Lizzy Johnston for the “*Cancer Risk Factors, Risk Reduction and Screening*” session at the 5th Cancer Council / AEA ECR Cancer Epidemiology Conference, November 2025, Virtual.

Best Presentation

Awarded to Dr Katelyn Collins for the “*Health Systems, Policies and Equity in Cancer*” session at the 5th Cancer Council / AEA ECR Cancer Epidemiology Conference, November 2025, Virtual.

People’s Choice Award

Awarded to Dr Katelyn Collins for her presentation on *Understanding kit non-receipt in the Australian National Bowel Cancer Screening Program* at the 5th Cancer Council / AEA ECR Cancer Epidemiology Conference, November 2025, Virtual.

Early Career Research Management Program Award

Awarded to Sabine Fletcher by the Australasian Research Management Society (ARMS) towards professional career development goals.

Appendix B: Grants

GRANTS AWARDED 2025-2026

Baade P. *Improving childhood cancer data* – CA-DATA-250711. Cancer Australia Services Contract. July 2025-May 2026. \$104,637.

Baade P, Collins L, Whiteman D. *LUMINAS: Long-term melanoma outcomes and health service utilisation examined through national data linkage and advanced statistical analyses*. Melanoma Institute Australia. Roadmap for a National Targeted Skin Cancer Screening Program Workstreams 1&4. 2025-2027. \$183,992.

Baade P. *Understanding and Addressing Prostate Cancer Disparities in Rural and Remote Communities: A Multi-faceted Approach (UNDERSTAND-RARC)*. Deed of Variation of

Collaboration Agreement to support Phase 2 qualitative research. November 2025 – August 2026. Cancer Council Queensland \$65,000.

Baade P. *Australian Cancer Atlas Updates* – F26/173. Cancer Australia Services Contract. June 2026 – June 2027. \$129,000.

Collins L, Collins K *Understanding patient experiences during opportunistic skin cancer checks*. Research Variation Agreement to support additional research Project 3. June 2026-December 2026. \$29,000.

Hayes S, Collins L. ECCQ | *Cancer-Free Cultures Project Services Agreement*. Queensland Cancer Strategy Partnership Funding Cancer Prevention and Screening



(Services contract). July 2025-June 2029. Total: \$783,333. Cancer Council Queensland: \$110,000.

Spence R, Hayes S. *Activate Program: Empowering the exercise oncology workforce: Co-designing professional development for national delivery to improve cancer outcomes*. Cancer Patient Support Program – Department of Health, Disability and Ageing. Dec 2025-June 2027. \$409,615.

GRANTS UNDERWAY 2025-2026

Adams L, Emery J, Jeffrey G, Thompson A, Strasser S, Crawford D, Collins L, Reid C, Wallace M, Chondros P. *The IC3 trial: Identifying cirrhosis and liver cancer in primary care*. MRFF 2020 Improving Diagnosis in Cancers with Low survival Rates. June 2021-May 2025. \$70,019.

Beesley V, Neale R, Turner M, Yates P, Wyld D, Chan R, Collins L. *PRoCESS: Pancreatic cancer Relatives Counselling and Education Support Service trial. Assessing the effect of nurse-led counselling, compared with information alone, on participant-reported outcomes and use of medical services*. MRFF Clinical Trials Activity – Rare Cancers, Rare Diseases and Unmet Need Initiative 2019. 2020-2025. \$801,229.

Bradford N, Trost S, Walker R, Tweedy S, Clanchy K, Hill J, Smith S, Collins L, Duff J, Marquart-Wilson L, McCarthy A, Spence R, Young K, Ross S. *APAP-YCS: a Co-designed adaption of the Adapted Physical Activity Program to promote lifestyle physical activity among young cancer survivors*. 2024 MRFF Survivorship Care and Collaborative Research Prioritisation. 2025-2029. \$1,983,854.

Chan R. *Implementation of a nurse-enabled, shared-care follow-up model for early Breast cancer survivors (The IBIS-Survivorship Study)*. NHMRC Partnership Grant January 2020-July 2026. \$15,540.

Chan R, Emery J, Yates P, Dunn J, Hart N, Koczwara B, Collins L, Jefford M, Vela I, Jones L. *A hybrid, implementation-effectiveness trial of a nurse-enabled, shared-care model between primary and acute care for prostate cancer survivors (The MOSES Trial)*. MRFF 2020 Primary Health Care Research. 2021-2025. \$1,625,286.65.

Collins L, Baade P. *Roadmap for a National Targeted Skin Cancer Screening Program Project 2: MST-25: Pilot Melanoma Screening Trial – 25-year follow-up study examined through national data linkage and advanced statistical analyses*. Melanoma Institute Australia – Roadmap for a National Targeted Skin Cancer Screening Program. 2025-2029. \$66,386.

Collins L, Canfell K, Baade P. *Roadmap for a National Targeted Skin Cancer Screening Program: Workstream 4* is to understand what the cost-effectiveness is of a proposed national skin cancer screening program. 2025-2028. \$300,000.

Collins L, Jongenelis M, Watt K, Larcombe A, Lindsay D, Lal A, Mitrou F, Marshall H. *Evaluating health economic and equity consequences of government regulations of e-cigarette use (E4 study)*. NHMRC 2024 Partnership Projects PRC3. August 2025-August 2027. \$346,681.

Gardiner F, Baade P, Smith D, Mengersen K, Cameron J, Nayak R, Goodwin B, Dunn J, Smith B, Frydenberg M. *Understanding and Addressing Prostate Cancer Disparities in Rural and Remote Communities: A Multi-faceted Approach (UNDERSTAND-RARC)*. November Prostate Cancer Health Equity Program. 2025-2026. \$295,000.

Garvey G, Howard K, Baade P, Butler T, Aitken J, Lawler S, Spurling G, Diaz A. *Achieving Equity in Cancer Screening for First Nations Peoples*. NHMRC 2023 Synergy Grants. 2024-2029. \$5,000,000.

Garvey G, Roder D, Diaz A, Baade P, Walpole E, Griffiths K, Howard K, Cossio D, Gall A. *A First Nations Cancer Cohort Study (CanCo)*. NHMRC 2022 Clinical Trials and Cohort Studies. 2024-2028. \$3,431,484.

Jenkins M, Wilson C, Emery J, Jinang J, Chang S, Macrae F, Baxter N, Goodwin B, Feletto E. *Tackling Australia's low screening participation to prevent bowel cancer screening morbidity and deaths (BestBowel)*. NHMRC Synergy Grant. 2022-2026. \$5,000,000.

Khosrotehrani K, Mar V, Campbell S, Collins L, Webster A, Chong A. *The SiroSkin study: A multi-centre randomised double-blind placebo-controlled trial of 1% topical sirolimus*

in the chemoprevention of facial squamous cell carcinomas in solid organ transplant recipients. MRFF 2021 Rare Cancers, Rare Diseases and Unmet Need. 2022-2027. \$2,486,489.

Merollini K, Wright H, Davis C, Rune K, Rose G, Johnston E, Ayre S, Hale H, Memess A, Surace J, McKay M, Hughes W. *Financial toxicity in regional & rural cancer survivors: Co-design of a holistic support program and implementation strategy (FINHOPE)*. LAUNCH (internal UniSC funding). January 2025-December 2025. \$30,000.

Mileshkin B, Ugalde A, Tothill R, Quinn S, Wong H-I, Prall O, Mitchell C, Wickramasinghe N, Fedele C, Collins L (AI). *Solving Unknown Primary cancer Earlier Diagnosis (SUPER-ED): A stepped wedge cluster randomised controlled trial implementing a new model of care to support earlier diagnosis*. 2020 MRFF – EPCDRI. 2021-2025. \$2,366,198.

Pattison DA, Wootton E, Francis R, Amjadeen M, Campbell L, McLeod D, Donovan P, Wong C, Pelecanos A, Collins L. *PARA-PET: a randomised trial of [18F] flurocholine PET/CT vs conventional imaging for primary hyperparathyroidism*. Queensland Health – Queensland Technology Future Fund. 2025-2027. \$244,246.

Pole J, Merolli K, Roberston E, Baade P, Bradford N, Nassar N. *Life and health After Childhood Cancer (LACE) a national linkage project*. Medical Research Future Fund – National Critical Research Infrastructure Initiative. 2024-2029. \$3,000,000.

Reeves M, Hayes S, Boyle F, Collins L, Morris M, McCarthy N, Chatfield M. *Optimising Care: Phase III trial in women with metastatic breast cancer to improve quality of life via exercise and diet*. MRFF 2021 Rare Cancers Rare Diseases and Unmet Need. 2022-2027. \$2,044,955

Webb P, Cohen P, Jordan S, Collins L, Spilsbury K, Codde J, Powell A, Grant P, Steer C, Stewart C. *Ovarian cancer: investigating Variation in care and survival, Aetiology and Risk factors to improve outcomes in Australia via National data linkage. The OVARIAN study*. Medical Research Future Fund (MRFF) – Emerging Priorities and Consumer Driven Research Initiative – 2019 Ovarian Cancer Research Grant Opportunity. 2020-2025. \$2,707,035.



Appendix C: Publications

Adams LA, de Guingand D, Jeffrey GP, Thompson AJ, Strasser SI, Crawford D, **Collins L**, Reid C, Wallace M, Chondros P, Allard N, Kirke A, Rutherford C, Hespe C, Partanen R, Frear S, Napreet H, Piakis K, Maas C, White OJ, Laughlin A, Clinton-McHarg T, Clymer C, Boyd L, Emery J. *The IC3 trial: protocol for a multi-centre individually randomised controlled trial to compare a cirrhosis detection and hepatocellular carcinoma surveillance pathway vs usual care in Australian general practice for 45-75-year-olds with risk factors for chronic liver disease*. *Trials*. 2025; 26(1):350. doi: 10.1186/s13063-025-09037-9

Ayre S, Ireland M, **Taglieri-Sclocchi A**, **Bourdaniotis X**, March S, Crawford-Williams F, Dunn J, Chambers S, **Goodwin B**, **Johnston E**. *Time from diagnosis to treatment: Are rural cancer patients receiving optimal care?* *Supportive Care in Cancer*. 2025; 34(1):18. doi.org/10.21203/rs.3.rs-6044124/v1

Ayre SK, **Madders RJ**, **Baker BP**, **Mitchell E**, **Goodwin BC**, **Johnston EA**, **Gallegos D**. *Food and Nutrition Insecurity in Cancer Survivorship: A Global Scoping Review*, *Cancer Medicine*. 2026; 15, no. 6 (2026): e71860, doi: 10.1002/cam4.71860.

Bainomugisa CK, **Cameron J**, **Dasgupta P**, **Baade P**. *The number of cancer-related deaths that could be attributable to spatial disparities in survival in Australia, 2010-2019: a retrospective population-based cohort study*. *The Medical Journal of Australia*. 2025; 223(11):593-601. doi:10.5694/mja2.70102

Bainomugisa CK, **Dasgupta P**, **Cameron JK**, **Cramb S**, **Strasser SI**, **MacLachlan JH**, **Baade PD**. *Spatial disparities in incidence and survival of liver cancer in Australia, 2010-2019*. *Cancer Epidemiology*. 2026; 102:103042. doi: 10.1016/j.canep.2026.103042

Bainomugisa CK, **Dasgupta P**, **Cameron JK**, **Tran B**, **Cramb SM**, **Baade PD**. *Spatial patterns of testicular cancer*

diagnosis in Australia, 2010-2019. Spatial and Spatio-temporal Epidemiology. 2025; 55:100745. doi: 10.1016/j.sste.2025.100745

Bradford N, **Whalan E**, **Condon P**, **Semerici R**, **Bowers A**, **Skrabal Ross X**. *Making Symptoms Visible: The Impact of Real-Time PROM Integration in Pediatric Oncology*. *Children*. 2026; 13(2):164. doi: org/10.3390/children13020164

Baldwin HJ, **Pont S**, **Currell A**, **Newey L**, **Youlden DR**, **Bradford N**, **Baade PD**, **Aitken JF**, **Pole JD**, **Nassar N**. *Data Resource Profile: The Life and health After Childhood cancer (LACE) project*. *International Journal of Population Data Science*. 2026; 8(6):2988. doi: 10.23889/ijpds.v8i6.2988

Bloomquist K, **Spence RR**, **Vagenas D**, **Pyke C**, **Sandler CX**, **Rye S**, **Young L**, **Hayes SC**. *Comparison of the effects of low- versus high-supervision exercise on breast cancer survivorship outcomes*. *JNCI Cancer Spectrum*. 2026; 10(1):pkag004.2026. doi: 10.1093/jncics/pkag004

Chapman A, **Gaskin CJ**, **Beks H**, **Wright C**, **Marshall S**, **Johnston EA**, **Bergin RJ**, **Riva S**, **Crawford-Williams F**, **Short CE**, **Kiss N**, **Lin Yoong S**, **Hart NH**, **Wong Shee A**, **Rodi H**, **Jongebloed H**, **Ugalde A**. *Implementation strategies for evidence-based healthcare interventions in rural and remote settings: a scoping review*. *The Lancet Regional Health - Western Pacific*. 2025; 66:101732. doi: 10.1016/j.lanwpc.2025.101732

Collins K, **Ireland M**, **Perry N**, **Jenkins M**, **McIntosh JG**, **Feletto E**, **Baxter NN**, **Goodwin B**. *The effect and psychological mediators of a redesigned invitation letter to increase bowel cancer screening intention and likelihood: A randomised controlled experiment*. *Patient Education and Counseling*. 2025; 139:109240. doi: 10.1016/j.pec.2025.109240

Collins K, **Pearse E**, **Plinsinga M**, **Taglieri-Sclocchi A**, **Day M**, **Goodwin B**, **March S**, **Ireland M**, **Johnston EA**. *Factors associated with pain among rural cancer survivors: findings*

from an Australian longitudinal study. *Supportive Care in Cancer*. 2026; 34(4). doi: 10.1007/s00520-026-10622-0

Collins LG, **Simpson PT**, **Lindsay D**, **Nones K**, **Ryan K**, **Fairbairn D**, **Fielding D**. *Cost-effectiveness analysis of four sampling and genomic testing strategies for patients with advanced non-small cell lung cancer in Australia*. *Pathology*. 2026; 58(4):411-419. doi: 10.1016/j.pathol.2025.12.007.

De Silva G, **Robertson EG**, **Bowers A**, **Schilstra C**, **Patel SK**, **McCarthy MC**, **McLoone J**, **Pole JD**, **Sansom-Daly UM**, **Oppelaar S**, **Cummings J**, **Bradford N**. *What Matters Most: The Top 10 Child and Adolescent Cancer Research Priorities in Australia*. *Health Expectations*. 2026; 29(3): e70689. doi: 10.1111/hex.70689.

DiSipio T, **Turner J**, **Da Silva W**, **Driscoll E**, **Preston M**, **Tran K**, **Varnier-Lui N**, **Yeoh H-L**, **Kaur D**, **Alsop K**, **Hayes SC**, **Janda M**, **Spence RR**. *Understanding Contemporary Endometrial Cancer Survivorship Issues: Umbrella Review and Healthcare Professional Survey*. *Cancers*. 2025; 17(16):2696. doi: 10.3390/cancers17162696

Goodwin B, **Myers LS**, **Baade P**, **Perry N**, **Muraswki B**, **Cameron J**, **Browne M**, **Collins LG**. *Mapping the Aggregated Behavioural Risk Factors for Colorectal Cancer by Small Areas Across Australia*. *Australian Journal of Rural Health*. 2026; 34(3):e70221. doi: 10.1111/ajr.70221.

Ho YM, **Merollini KMD**, **Collins LG**. *Timing and Frequency of Surveillance Colonoscopies After Resection for Colorectal Cancer in Queensland, Australia: A Retrospective 10-year Analysis*. *Journal of Gastroenterology and Hepatology Open*. 2025; 9(9):e70266. doi: 10.1002/jgh3.70266

Ho YM, **Merollini KMD**, **Collins LG**. *Timing Intervals and Frequency of Adenoma Surveillance Colonoscopies in Central Queensland, Australia*. *ANZ Journal of Surgery*. 2026; 96(4):935-946. doi: 10.1111/ans.70517.

Huynh TNT, **DiSipio T**, **Collins LG**, **Jones L**, **Neale RE**,

Beesley VL. *Cancer patient distress and health service use is linked with carer distress: evidence from a systematic review and meta-analysis*. Supportive Care in Cancer. 2026; 30;34(6):594. doi: 10.1007/s00520-026-10759-y.

Jahan S, **Lindsay D**, Diaz A, Li M, Cunningham J, Garvey G. *Exploring the Costs of Hospital and Emergency Department Utilisation in the First Three Years After Diagnosis for Adults Diagnosed With Pancreatic Cancer in Queensland, Australia*. Cancer Medicine. 2025; 14(17):e71193. doi: 10.1002/cam4.71193

Jahan S, **Lindsay D**, Diaz A, Li M, Griffiths K, Olver I, Garvey G. *End-of-life healthcare use and associated costs for First Nations Australians diagnosed with cancer in Queensland, Australia*. Supportive Care in Cancer. 2025; 33(8):669. doi: 10.1007/s00520-025-09725-x.

Johnston EA, Bourdaniotis XB, Ayre SK, Fung H, Craig N, Crawford-Williams F, Bergin RJ, Emery JD, Chan RJ, Goodwin BC. *What are the Facilitators and Barriers to Improving the Delivery of Survivorship Care Information to Rural Cancer Survivors? A Qualitative Study Using an Implementation Science Framework*. Australian Journal of Rural Health. 2025; 33(6):e70125. doi: 10.1111/ajr.70125

Johnston EA, Bourdaniotis XE, Ayre SK, Oster M, Romain D, Goodwin BC. *A social return on investment analysis of a free meal program to support rural cancer patients and caregivers travelling for treatment*. Supportive Care in Cancer. 2025; 33(7):602. doi: 10.1007/s00520-025-09662-9

Kenkhuis MF, Doorenbos M, Mast IH, Aaronson NK, van Beurden M, Bohus M, Courneya KS, Daley AJ, Galvão DA, Goedendorp MM, van Harten WH, **Hayes SC**, Hiensch AE, Irwin ML, Kersten MJ, Knoop H, May AM, McConnachie A, van Mechelen W, Mutrie N, Newton RU, Nollet F, Oldenburg HS, Schmidt ME, Schmitz KH, Schulz KH, Sonke GS, Steindorf K, Stuiver MM, Taaffe DR, Thorsen L, Velthuis MJ, Wiskemann J, Mesters I, Ulrich CM, van Vulpen JK, Custers JAE, Buffart LM. *Exercise effects on symptoms of depression and anxiety vary by patient, clinical, and intervention characteristics in cancer survivors: Results from pooled analyses of individual participant data of 26 RCTs*. Supportive Care in Cancer. 2025; 33(7):647. doi: 10.1007/s00520-025-09646-9

s00520-025-09646-9

Kerr E, Tan R, Parkinson L, Turpin M, Carter A, **Bradford N**, Simons M. *How Could the Procedure be Done to Care for Them? An Interpretive Description Study of Procedural Care in a Pediatric Oncology Setting*. Seminars in Oncology Nursing. 2026; 42(1):152118.

Kou K, Cameron J, Dasgupta P, Chen H, **Baade PD**. *Generation of machine-learning derived cancer vulnerability indicator to determine the spatial burden of cancer outcomes*. PLoS One. 2026; 21(2):e0319539. doi: 10.1371/journal.pone.0319539

Li V, Cosgrove S, **Collins K**, Baden P, Blennerhassett R, Chan B, Chan L, Day D, **Goodwin B**, Kwok A, Packham D, Kyaw K, Todaro C, Webber K, Williams J, Zengin A, Grech L. *Management of bone health in cancer survivorship: a systematic review of clinical guidelines*. Osteoporosis International. Published Online. 2026 doi: 10.1007/s00198-026-07924-8

Li X, Mielke G, **Goodwin B, Stiller A, Murawski B**. *Does experiencing a major life event influence physical activity and fruit and vegetable intake in Australian adults? A cross-sectional study*. Psychology, Health & Medicine. 2026. 1-15. doi: 10.1080/13548506.2026.2645956.

Lim M, **Bradford N**, Brain D, Senanayake S, Kularatna S, Young K, Cashion C, Hassall T, Cramb S. *Financial Burden Associated With Hospitalisation Among Families of Childhood Brain Tumours in Australia*. Pediatric Blood & Cancer. 2026;73(7): e70353. doi: 10.1002/1545-5017.70353

Lindsay D, Collins L, Olsen C, Pandeya N, Whiteman D. *The costs of diagnosing and treating skin cancer: Findings from the QSkin Study*. Australia and New Zealand Journal of Public Health. 2026;100326. doi: 10.1016/j.anzjph.2026.100326.

Lindsay D, Stangl S, Ronagh K, **Cameron J**, Johns R, Muir J, **Collins LG**. *Mapping the Current Demand and Supply of Dermatologists and General Practitioners Managing Skin Cancer in Queensland, Australia*. Australasian Journal of Dermatology. 2026;67(4): 214–227. doi: 10.1111/ajd.70063.

Marshall S, Fahey M, van der Meij B, de van der Schueren M, Leigh L, **Johnston E**, Wright C, Rogan R, Crichton M, Rodi H, Chapman A, Tang X, Ugalde A. *Family-centred telehealth-enhanced dietary counselling for the treatment of protein-energy malnutrition in rural-living older adults transitioning from rehabilitation to home: A pilot controlled trial*. Journal of Human Nutrition and Dietetics. 2026; 39(3): e70291. doi:10.1111/jhn.70291.

Marshall S, Wright C, Leigh L, Riva S, Crichton M, Rodi H, Jongebloed H, **Johnston EA**, Bergin RJ, Chapman A, Crawford-Williams F, Hart NH, Alston L, Rhee J, Gao L, Gunn K, Ugalde A. *Association of rurality status with all-cause and cancer-specific survival: a systematic review and meta-analysis adjusting for clinical factors, demographics, and geographical remoteness*. The Lancet Regional Health - Western Pacific. 2026; 66:101744. doi: 10.1016/j.lanwpc.2025.101744

Martos M, George N, Arreguin-González FE, Baassiri M, Benito-Reséndiz AE, Bhakta N, Bhatt NS, **Bradford N**, Ehrhardt MJ, Fajardo D, Hudson MM, Jiménez-Carbajal MG, Lam Shang Leen J, Mbah Afungchwi G, Mueller C, Olsson M, Poudyal I, Pritchett N, Ramirez O, Ritter J, Radhakrishnan V, Sharma KS, Sijecic A, Valencia MC, Zaidi A, Van Zyl A, Force LM. *Childhood Cancer Survivorship Globally: A Systematic Review*. JAMA Oncology. 2025; 11(10):1231-1238. doi:10.1001/jamaoncol.2025.2506

McIntosh J, **Goodwin B**, Ait Ouakrim D, **Collins K**, Wilson C, Baxter N, Jiang J, Mahar R, Flander L, Emery J, Chang S, Taylor N, Feletto E, Lew J, Canfell K, Macrae F, Greenwell H, Jenkins M. *Testing interventions to increase participation in the National Bowel Cancer Screening Program among persistent never-screeners: study protocol for a randomised controlled trial*. Trials. 2026; 27(1):329. doi: 10.1186/s13063-026-09553-2

Murawski B, Collins KE, Viljoen B, Pearse EC, Vicario J, Stiller A, Grennan H, Brown G, Woods L, March S, **Goodwin B**. *Co-design of Lifestyle6, a digital tool targeting multiple health behaviour changes for cancer risk reduction and early detection support*. PLoS One. 2026; 21(4):e0347311. doi: 10.1371/journal.pone.0347311

Nabulaku D, **Collins LG**, **Lindsay D**, Lowe JL, Merollini KMD. *Hospitalisations and Costs of Chronic Health Conditions Among Long-Term Survivors of Childhood, Adolescent, and Young Adult Cancers in Queensland, Australia*. *Psycho-Oncology*. 2026; 35(2):e70395. doi: 10.1002/pon.70395

Neale RE, Jordan SJ, Thompson B, Bernardes CM, Adams J, Baggoley C, Barreto SG, Baxter CM, Croagh D, Devereaux B, Emery J, **Collins LG**, Gilhotra R, Grogan P, Hourigan L, Martinez-Gutierrez J, Metz AJ, Philcox S, Rafiq M, Rhee J, Schrader S, Stewart M, Windsor J, Zalcberg J, Waterhouse M. *The sensitivity of decision support tools for identifying patients with pancreatic cancer: an observational study*. *British Journal of General Practice Open*. 2026;BJGPO.2025.0142. doi: 10.3399/BJGPO.2025.0142.

Ngo P, Shah R, Vignat J, **Collins L**, Cunnam L, Hwang I, Bray F, Yabroff R, Soerjomataram I. *The direct costs of cancer care: a review trends and variations in 39 countries*. *Journal of the National Cancer Institute Monographs*. 2026; 72:3-14. doi: 10.1093/jncimonographs/lgag005

Penny R, Keogh S, Shergold J, **Bradford N**. *The Use of Patient-Reported Outcome Measures in Paediatric Haematopoietic Stem Cell Transplant: A Systematic Review*. *Children*. 2026;13(4):491.

Retell J, **Francis S**, **Rene J**, **Baade P**. CaRDO: A Tool for Empowering Cancer Registries to Publish Population-Level Cancer Statistics Online. *Journal of Registry Management*. 2025; 52(4):146-150.

Rolfe ML, Miller E, Donkin L, Ekberg S, **Bradford NK**. *Co-Designing a National Family Handbook for Childhood Brain Tumor*. *Children*. 2025; 12(9):1126. doi: 10.3390/children12091126.

Reul-Hirche HM, Dunn MR, **Plinsinga ML**, Laakso EL, Troester MA, **Hayes SC**. *The relationship between impaired upper-body function, quality of life and breast cancer-related lymphoedema: results from a prospective, population-based cohort study*. *Breast Cancer Research and Treatment*. 2026; 215(3):73. doi: 10.1007/s10549-025-07877-2

Şahin RS, Moore E, Savaş EH, Aksu M, Bay F, Gates P, Cook O, Taylor K, Williams N, McErlean G, **Bradford N**. *Role Perceptions and Workplace Challenges Among Oncology Nurses: A Comparative Study of Türkiye and Australia*. *Seminars in Oncology Nursing*. 2026;42(3):152243. doi: 10.1016/j.soncn.2026.152243

Saulicz A, **Abernethy D**, Wraith D. *Can too much exercise kill you? A systematic review of the risk of a cardiovascular event or death from long term strenuous exercise*. *European Journal of Epidemiology*. 2026;41(6):715-733. doi: 10.1007/s10654-025-01353-3.

Susanto A, **Lindsay D**, **Collins LG**. *Chemoprevention of Keratinocyte Carcinomas and Actinic Keratoses In Immunocompetent Patients: A Systematic Review*. *Clinical and Experimental Dermatology*. 2026;51(7):1202-1212. doi: 10.1093/ced/llag073.

Taglieri-Sclocchi A, Bindicsova I, **Ayre SK**, Ireland M, March S, Crawford-Williams F, Chambers S, Dunn J, **Goodwin BC**, **Johnston EA**. *Rural Cancer Survivors' Perceived Delays in Seeking Medical Attention, Diagnosis, and Treatment: Findings From a Large Qualitative Study*. *Cancer Medicine*. 2025;14(14):e71036. doi: 10.1002/cam4.71036.

Tran V, Duarte Romero BL, Andersen H, Clarke M, **Collins LG**, Dawson T, Hartel G, Lefevre JG, Lucas RM, McLeod DSA, Milne RL, Sinclair C, Whiteman DC, Waterhouse M, Neale RE. *Effect of daily sunscreen application on vitamin D: findings from the open-label randomised controlled Sun-D Trial*. *British Journal of Dermatology*. 2025;193(6):1128-1137. doi: 10.1093/bjd/ljaf310.

Ugalde A, Jongebloed H, Wright C, Rodi H, Chapman A, Marshall S, Aras D, Bergin RJ, Boffa S, Boltong A, Conlin M, Crawford-Williams F, de Wet C, Faisal W, Gao L, Gasper H, Gunn K, Hart NH, Hayes T, Honeyball F, **Johnston EA**, Karikios D, Kiss N, Leigh L, Livingston PM, O'Kane C, Perry R, Rhee J, Riva S, Sergeant L, Short CE, Stewart R, Turner V, Varlow M, Whittaker K, Wong Shee A, Yoong S, Alston L. *Towards equitable cancer outcomes for rural and remote communities: reflections, lessons and recommendations*. *The Lancet Regional Health - Western Pacific*. 2026; 66:101756. doi: 10.1016/j.lanwpc.2025.101756

van der Pols J, **Johnston EA**, Whitehall V, Ibiebele T, Hewett D, Leggett B. *Dietary pattern and lifestyle risk factors for sessile serrated precursors to colorectal cancer*. *British Journal of Nutrition*. 2025;134(1):35-46. doi: 10.1017/S0007114525103747

White GL, Capozzi LC, Linton C, Wright A, Jones T, Wright HH, Bolam KA, **Johnston EA**, Clifford BK, Bean K, Brown S, Kolesaric S, Kennedy MA, Chan BA, Rose GL. *Triage tools to inform the prioritization of physical health services following a diagnosis of cancer: a scoping review*. *Supportive Care in Cancer*. 2025; 33(9):760. doi: 10.1007/s00520-025-09816-9.

Wright C, Riva S, Crichton M, Rodi H, Jongebloed H, Leigh L, **Johnston EA**, Bergin RJ, Chapman A, Alston L, Crawford-Williams F, Hart NH, Rhee J, Gao L, Gunn K, Gasper H, Ugalde A, Marshall S. *Measuring cancer equity globally: harmonising international rural-urban classifications for exploring cancer outcomes*. *The Lancet Regional Health - Western Pacific*. 2025; 66:101737. doi: 10.1016/j.lanwpc.2025.101737

Young K, Malatzky C, **Bradford N**. *Together and Apart: A Gender-Informed Qualitative Analysis of Childhood Brain Tumour and the Parental Relationship*. *Psycho-Oncology*. 2025; 34(9):e70274. doi: 10.1002/pon.70274

Zajdlewicz L, **Goodwin BC**, **Pearse E**, Crawford-Williams F, **Johnston EA**. *Subsidy Schemes to Alleviate the Burden of Travelling for Healthcare: A Brief Report on Users' Experiences in Queensland, Australia*. *Health Promotion Journal of Australia*. 2026; 37(3): e70207, doi: 10.1002/hpja.70207.



Appendix D: Presentations

EVENT REPRESENTATIONS AND CONFERENCE ACTIVITIES

Bradford N. International Children's Palliative Care Network Conference. Session Co-Chair. November 2025, Manila, Philippines.

Bradford N. *Supportive Care and Treatment* session. ANZCHOG. Session Co-Chair. August 2025, Brisbane.

Bradford N. *Promoting professional wellbeing and reducing burnout in children's cancer*. Session Co-Chair. SIOP 2025 International Society of Pediatric Oncology, October 2025, Amsterdam, Netherlands.

Bradford N. *Top Abstract Session*. Session Co-Chair. SIOP 2025 International Society of Pediatric Oncology, October 2025, Amsterdam, Netherlands.

Bourdaniotis X. EIS: Evidence & Implementation Summit 2025. Representative. October 2025, Melbourne.

Bourdaniotis X. UniSC Cancer Survivorship Seminar. Hosted by University of Sunshine Coast. Representative. October 2025, Sunshine Coast.

Bourdaniotis X. 5th Cancer Council / AEA Cancer Special Interest ECR Conference. Event Representative. November 2025, Virtual.

Collins L. Mini Expo Stallholder - UQPHA Research Night. Hosted by QUT. Representative. September 2025, Brisbane.

Hayes S. *Best of the Best Orals: Epidemiology*. COSA-IPOS 2025 Annual Scientific Meeting. Session Chair. November 2025, Adelaide.

Hayes S. *The role of the MDT in supporting beneficial exercise and diet behaviours*. COSA-IPOS 2025 Annual Scientific Meeting. Session Co-Chair. November 2025, Adelaide.

Spence R. *The role of the MDT in supporting beneficial exercise and diet behaviours*. COSA-IPOS 2025 Annual Scientific Meeting. Session Co-Chair. November 2025, Adelaide.

PRESENTATIONS

Ayre S. *A scoping review exploring the current landscape of food and nutrition insecurity research in cancer survivorship*. Poster. COSA-IPOS 2025 Annual Scientific Meeting, November 2025, Adelaide.

Ayre S. *Cancer survivorship research in Queensland*. Invited Speaker. UniSC Cancer Survivorship Seminar, October 2025, Sunshine Coast.

Ayre S. *The current landscape of food and nutrition insecurity research in cancer survivorship: A global systematic scoping review*. MASCC/ISOO 2026 Annual Meeting, June 2026, Melbourne.

Ayre S. *Food and nutrition insecurity in cancer survivorship: Findings from a scoping review*. Invited Speaker. Brisbane Cancer Conference 2025, November 2025, Brisbane.

Ayre S. *Time from diagnosis to treatment: Are cancer patients who travel for treatment receiving optimal care in Australia?* Abstract Presentation. 5th Cancer Council / AEA Cancer SIG ECR Epidemiology Conference, November 2025, Virtual.

Ayre S. *Time from diagnosis to treatment: Are rural patients with cancer receiving optimal care in Australia?* MASCC/ISOO 2026 Annual Meeting, June 2026, Melbourne.

Ayre S. *Using an implementation science framework to map facilitators and barriers to improving the delivery of survivorship care information to rural cancer survivors*. Abstract Presentation. COSA-IPOS 2025 Annual Scientific Meeting, November 2025, Adelaide.





Ayre S. *SNACCS: Supporting Nutrition Among Childhood Cancer Survivors*. Queensland Collaborative for Cancer Survivorship (QCCS) Mid-Year Seminar, June 2026.

Baade P. *Australian Cancer Atlas: Background, Content and Screening*. Invited Speaker. Cancer Screening and Immunization (CSI) Committee, February 2026, Virtual.

Baade P. *The Australian Cancer Atlas: Enabling Discovery and Decision-Making across Australia*. Invited Webinar. Cancer Nurses Society of Australia Webinar, March 2026, Virtual.

Baade P. *The Australian Cancer Atlas: Enabling Discovery and Decision-Making across Australia*. Invited Speaker. AEA Cancer Special Interest Group, June 2026, Webinar.

Baade P. *The Australian Cancer Atlas: Enabling Discovery, Decision-Making, and Digital Innovation*. Invited Plenary. Brisbane Cancer Conference 2025, November 2025, Brisbane.

Baade P. *Building on the platform of the Australian Cancer Atlas - results and opportunities for expansion*. Abstract Presentation. 2025 IACR Conference, November 2025, Izmir, Türkiye.

Baade P. *CaRDO: Cancer Registry Data Online*. Abstract Presentation. 2025 IACR Conference, November 2025, Izmir, Türkiye.

Baade P. *Examining spatial patterns in breast cancer screening across Australia through the Australian Cancer Atlas*. Abstract Presentation. BreastScreen Australia Conference, March 2026, Brisbane.

Baade P. *Viertel Cancer Research Centre - Update*. Invited Speaker. CCQ Breast and Prostate Cancer Nurse's Practicum, October 2025, Brisbane.

Baade P. *Patterns of liver cancer*. Invited Speaker. ASHM Webinar - Hot Topics - Liver Cancer. June 2026. Online.

Bainomugisa C. *Cancer-related deaths attributable to spatial disparities in survival*. Abstract Presentation, presented by Lizzy Johnston. Are you Remotely Interested (AYRI) Conference 2025: Keeping on Track for Health

Equity in the Bush, July 2025, Kalkatunga Country, Mt Isa.

Bainomugisa C. *From Maps to Meaning: What Spatial Patterns Tell Us About Liver Cancer in Australia*. Invited Speaker. Brisbane Cancer Conference 2025, November 2025, Brisbane.

Bainomugisa C. *Spatial variation in incidence of testicular cancer in Australia, 2010-2019*. Abstract Presentation. Australasian Epidemiological Association 2025 Scientific Meeting, July 2025, Hobart.

Bainomugisa C. *Spatial variation in liver cancer incidence and survival in Australia, 2010-2019*. Abstract Presentation. 5th Cancer Council / AEA Cancer SIG ECR Epidemiology Conference, November 2025, Virtual.

Bainomugisa C. *Spatial variation in liver cancer incidence and survival in Australia, 2010-2019 and cancer-related deaths*. Invited Webinar. Cancer Nurses Society of Australia Webinar, March 2026, Virtual.

Bainomugisa C. *Understanding Geographic Variation in Cancer Outcomes*. Invited Speaker. AEA Cancer Epidemiology Interest Group. Online.

Baker B. *Highlighting evidence amongst misinformation: Dietitian insights from delivering a diet and exercise intervention for women with metastatic breast cancer*. Invited Speaker. Talking about the 'C' Word: Collaboration in Cancer Nutrition Care, September 2025, Melbourne.

Baker B. *The specialised role of a dietitian providing support to women with metastatic breast cancer: insights from the Optimising Care study*. Invited Speaker. COSA-IPOS 2025 Annual Scientific Meeting, November 2025, Adelaide.

Baker B. *The effect of exercise and diet interventions on cancer survival: Characteristics of randomised controlled trials included in a living systematic review and network meta-analysis*. QCCS mid-year seminar. June 2026. Brisbane.

Bourdaniotis X. *Evaluation of a community-based cancer counselling service for people affected by cancer: A mixed method study*. Abstract Presentation. COSA-IPOS 2025

Annual Scientific Meeting, November 2025, Adelaide.

Bourdaniotis X. *Evaluation of a community-based cancer counselling service for people affected by cancer: a mixed method study*. Oral rapid e-poster. MASCC/ISOO 2026 Annual Meeting, June 2026, Melbourne.

Bourdaniotis X. *Understanding the needs, preferences and ideas for a peer support group for women affected by cancer: Co-design Phase 1*. Invited Speaker. Brisbane Cancer Conference 2025, November 2025, Brisbane.

Bourdaniotis X. *Understanding the needs, preferences and ideas for a peer support group for women with cancer and women carers: co-design phase 1*. Oral rapid e-poster. MASCC/ISOO 2026 Annual Meeting, June 2026, Melbourne.

Bradford N. *Addressing Gaps to Measure Suffering: Promoting Research in Children's Palliative*. Invited Speaker. International Children's Palliative Care Network 2025 Conference, November 2025, Manila, Philippines.

Bradford N. *Care Beyond Cure: Integrating Health Promotion into AYA Cancer Survivorship*. Invited Speaker. Queensland Youth Cancer Forum, August 2025, Brisbane.

Bradford N. *Childhood Cancer Survival in Australia: A population-based analysis of prognostic indicators and survival disparities by geography and socio-economic status*. Abstract Presentation. ANZCHOG ASM 2025, July 2025, Brisbane.

Bradford N. *Empowering Families: Technology-Driven Support for Children with Cancer*. Invited Speaker. International Society of Pediatric Oncology (SIOP) Supportive Care Network Webinar, September 2025, Virtual.

Bradford N. *Identifying research priorities in children's cancer*. Invited Speaker. Children's Cancer CoLab Survivorship Reference Group meeting, November 2025, Virtual.

Bradford N. *Improving cancer care through innovation*. Invited Plenary. Kids Cancer Alliance

Symposium 2025, October 2025, Sydney.

Bradford N. *The Long Game: Building better futures for children adolescents and young adults after cancer*. Invited Plenary. Brisbane Cancer Conference 2025, November 2025, Brisbane.

Bradford N. *Workforce matters: Cancer nursing insights to improve culture and quality outcomes*. Invited Speaker. COSA - Clinical Oncology Society of Australia. November 2025. Sydney.

Bradford N. *Learnings from PROMs*. Invited Speaker. Patient Reported Outcome Measure Round table. June 2026. Sydney.

Bradford N. *A Randomised Controlled Trial of Medicinal Cannabis in Children with Advanced Cancer – Home Care and Rural Considerations*. Abstract Presentation. MASCC. June 2026. Melbourne.

Cameron J. *The Australian and Dutch Cancer Atlases and geographic inequalities in cancer*. Oral Presentation. International Data Week, October 2025, Brisbane.

Cameron J. *Impact and applications of the Australian Cancer Atlas*. Invited Webinar. Cancer Nurses Society of Australia Webinar, March 2026, Virtual.

Cameron J. *One in 10 cancer-related deaths could be avoided by reducing spatial disparities*. Oral Presentation. Australasian Epidemiological Association 2025 Scientific Meeting, July 2025, Hobart.

Cameron J. *Spatial estimates of cancer-specific mortality and survival provide different interpretations*. Oral Presentation. Australasian Epidemiological Association 2025 Scientific Meeting, July 2025, Hobart.

Cicchini S. *Empowering the Exercise Oncology Workforce through Co-Designed Professional Development*. Abstract Presentation. Queensland Collaborative for Cancer Survivorship mid-Year Seminar. June 2026. Brisbane.

Collins K. *The content and psychometric properties of measures used to assess cancer screening related*

anxiety. Invited Speaker. MASCC/ISOO 2026 Annual Meeting, June 2026, Melbourne.

Collins K. *Factors associated with pain among rural cancer survivors: data from an Australian longitudinal study*. Abstract Presentation. COSA-IPOS 2025 Annual Scientific Meeting, November 2025, Adelaide.

Collins K. *Factors associated with pain among rural cancer survivors*. Invited Speaker. MASCC/ISOO 2026 Annual Meeting, June 2026, Melbourne.

Collins K. *The content and psychometric properties of measures used to assess cancer screening related anxiety*. Invited Speaker. MASCC/ISOO 2026 Annual Meeting, June 2026, Melbourne.

Collins K. *Understanding kit non-receipt in the Australian National Bowel Cancer Screening Program*. Invited Speaker. 5th Cancer Council / AEA Cancer SIG ECR Epidemiology Conference, November 2025, Virtual.

Collins L. *Building a New Prevention Investment Framework - Preparing our response to the Productivity Commission Draft Report on Health*. Invited Speaker. PHAA - Webinar - Building a New Prevention Investment Budget Framework, August 2025, Virtual.

Collins L. *Cost-effectiveness of genomic testing in advanced NSCLC: four strategies compared*. Abstract Presentation. Brisbane Cancer Conference 2025, November 2025, Brisbane.

Collins L. *E-cigarette regulations in Australia - evaluating the health and equity consequences*. Abstract Presentation. International Health Economics Association Congress 2025, July 2025, Bali, Indonesia.

Collins L. *Protocol for modelling the health and economic effects of Australia's e-cigarette policy*. Abstract Presentation. PHAA Preventive Health Conference 2026, May 2026, Hobart.

Collins L. *UV Protection in Sports – Policies and Focus Group Findings*. Invited Speaker. Australian Society of Dermatologists, May 2026, Melbourne.



Halahakone U. *Impact of Nurse-Led Telehealth Support on Carer and Patient Outcomes in Pancreatic Cancer: An economic evaluation plan with Concept Questions to Audience*. Abstract Presentation. Queensland Collaborative for Cancer Survivorship mid-year seminar, June 2026, Brisbane.

Haroon M. *Visual explainers as a tool to communicate the impact of cancer in Australia*. Invited Webinar. Cancer Nurses Society of Australia Webinar, March 2026, Virtual.

Haroon M. *Visual explainers as a tool to communicate the impact of cancer in Australia*. Invited Speaker. Shorthand Roundtable Brisbane 2026, June 2026.

Hayes S. *Can exercise prevent cancer-related lymphoedema?* Abstract Presentation. 30th ISL World Congress of Lymphology, October 2025, Antalya, Türkiye.

Hayes S. *Changes in upper-body function predict breast cancer-related lymphoedema: results from a prospective, population-based cohort study*. Abstract Presentation. 30th ISL World Congress of Lymphology, October 2025, Antalya, Türkiye.

Hayes S. *Does adding exercise to chemotherapy for newly diagnosed ovarian cancer impact survival and quality of life?* Invited Plenary. Brisbane Cancer Conference 2025, November 2025, Brisbane.

Hayes S. *Exercise therapy added to first-line chemotherapy for ovarian cancer: Effects on progression-free survival and physical wellbeing in the randomised, phase 3 ECHO trial*. Abstract Presentation. IGCS 2025 Annual Global Meeting, November 2025, Cape Town, South Africa.

Hayes S. *Lower Limb Lymphoedema - what is it, why are we measuring it in our clinical trials and how are we measuring it?* Invited Speaker. Workshop for staff of Qld Centre for Gynaecological Cancer Research, UQ Centre for Clinical Health Research, July 2025, Brisbane.

Hayes S. *Muscle matters: practical approaches to body composition, nutrition and optimising muscle health in cancer care*. Invited Panel Member. COSA-IPOS 2025 Annual Scientific Meeting, November 2025, Adelaide.

Hayes S. *The role of the MDT in supporting beneficial exercise and diet behaviours*. Breakfast Symposium Co-coordinator and Session Co-Chair. COSA-IPOS 2025 Annual Scientific Meeting, November 2025, Adelaide.

Jensen S. *Addressing the forgotten sex in lymphedema research: Risk factors, incidence, and progression of lymphedema among men with prostate cancer. The AWARE cohort*. Abstract Presentation. 5th Cancer Council / AEA Cancer SIG ECR Epidemiology Conference, November 2025, Virtual.

Jensen S. *Comprehensive assessment of lower limb edema and its association with quality of life among men with prostate cancer*. Invited Speaker. Brisbane Cancer Conference 2025, November 2025, Brisbane.

Johnston E. *Dietary pattern and lifestyle risk factors for sessile serrated precursors to colorectal cancer*. Abstract Presentation. 5th Cancer Council / AEA Cancer SIG ECR Epidemiology Conference, November 2025, Virtual.

Johnston E. *Facilitators and barriers to improving survivorship care for rural cancer survivors*. Abstract Presentation. Are you Remotely Interested (AYRI) Conference 2025: Keeping on Track for Health Equity in the Bush, July 2025, Kalkatungu Country, Mount Isa.

Johnston E. *"I'm not the one with cancer but it's affecting me just as much": Supporting people living in rural and remote areas and caring for someone with cancer*. Invited Speaker. COSA-IPOS 2025 Annual Scientific Meeting, November 2025, Adelaide.

Johnston E. *Optimal methods for recruiting a large, diverse sample of cancer survivors to a registry-based qualitative study to inform service delivery*. Abstract Presentation. Queensland Collaborative for Cancer Survivorship (QCCS) mid-year seminar, June 2026, Brisbane.

Johnston E. *Tools and strategies for discussing and supporting diet and exercise behaviours*. Breakfast Symposium Co-ordinator/Invited Panel Member. COSA-IPOS 2025 Annual Scientific Meeting, November 2025, Adelaide.

Johnston E. *What are the best methods for recruiting a large, diverse sample of cancer survivors to a registry-based qualitative study?* Oral rapid e-poster presentation. MASCC/ISOO 2026 Annual Meeting, June 2026, Melbourne.

Kou K. *Machine Learning Analysis of Factors Associated with Geographic Inequities in Prostate Cancer Survival in Australia*. Invited Speaker. Chinese Congress on Holistic Integrative Oncology, November 2025, Kunming, China.

Kou K. *A machine learning framework for interpreting cancer outcome variation and supporting equity. Using geographic data to inform policy - Data Insights from the Australian Cancer Atlas*. Invited Speaker. Cancer Australia, April 2026, Online.

Kou K. *A machine learning framework for interpreting cancer outcome variation and supporting equity. Using geographic data to inform policy - Data Insights from the Australian Cancer Atlas*. Invited Speaker. Cancer Australia, AIHW, Department of Health, Disability and Ageing, June 2026, Online.

Langford J. *Unmet financial needs and support-seeking among rural Queensland cancer survivors*. Abstract Presentation. COSA-IPOS 2025 Annual Scientific Meeting, November 2025, Adelaide.

Langley R. *Supportive care needs of culturally and linguistically diverse communities affected by cancer and methods for gathering this information: A scoping review of the Australian context*. Invited Speaker. Brisbane Cancer Conference 2025, November 2025, Brisbane.

Lemus I. *Patient-reported outcome measures in colorectal cancer survivorship research: Measuring what matters most*. Abstract Presentation. 5th Cancer Council / AEA Cancer SIG ECR Epidemiology Conference, November 2025, Virtual.

Lindsay D. *Estimating the costs of in situ and thin invasive melanoma overdiagnosis in Australia*. Abstract Presentation. International Health Economics Association Congress 2025, July 2025, Bali, Indonesia.

Lindsay D. *From Costs to Consequences: What Defines Value in Healthcare?* Invited Speaker. ANZUP Annual Scientific Meeting 2026, June 2026, Adelaide.

Lindsay D. *Lives lost, work interrupted: estimating paid and unpaid productivity losses from cancer mortality.* Invited Plenary. Brisbane Cancer Conference 2025, November 2025, Brisbane.

Lindsay D. *Productivity losses from premature cancer mortality in Australia.* Abstract Presentation. Preventive Health Conference 2026, May 2026, Hobart.

Lindsay D. *Sun Safety in Sport.* Invited Speaker. Global Sport University Network 2025, September 2025, Brisbane.

Lindsay D. *Equity considerations in health economics analysis.* Invited Speaker. ANZUP Annual Scientific Meeting 2026, June 2026, Adelaide.

Lindsay D. *Living in the Sunshine State: Exploring patterns of sun exposure in a large population-based Queensland cohort.* Invited Speaker. ASSC Seminar Series June 2026, Brisbane.

Martin J. *Physical Activity and Exercise for Brain Tumours: Understanding the Why and Navigating the How.* Invited Speaker. 17th COGNO ASM, BTAA Patient Education and Information Forum, September 2025, Gold Coast.

Plinsinga M. *Cancer-related lymphoedema: Updated incidence estimates and the preventive effect of exercise – evidence from two systematic reviews and meta-analyses.* Abstract Presentation. Brisbane Cancer Conference 2025, November 2025, Brisbane.

Plinsinga M. *Can exercise prevent cancer-related lymphoedema?* Poster. COSA-IPOS 2025 Annual Scientific Meeting, November 2025, Adelaide.

Retell J. *CaRDO: A new tool for publishing population-level cancer statistics online.* Abstract Presentation. SciDataCon, October 2025, Brisbane.

Retell J. *CaRDO: An Online Reporting Tool for Population-Based Cancer Registries.* Abstract Presentation. NAACCR 2026 Virtual Conference, June 2026, Virtual.

Reul-Hirche H. *Changes in upper-body function predict breast cancer-related lymphoedema: results from a prospective, population-based cohort study.* Invited Speaker. Brisbane Cancer Conference 2025, November 2025, Brisbane.

Ryding H. *Delivering nutritional care to cancer survivors in primary care: Dietitians' perspectives and practices.* Abstract Presentation. 5th Cancer Council / AEA Cancer SIG ECR Epidemiology Conference, November 2025, Virtual.

Spence R. *Effects of exercise therapy during chemotherapy for ovarian cancer on progression-free survival and physical wellbeing (ECHO trial).* Abstract Presentation. Activate Conference (ESSA National ASM) 2026, April 2026, Adelaide.

Spence R. *MDT panel - challenging cases.* Invited Panel Member. COSA-IPOS 2025 Annual Scientific Meeting, November 2025, Adelaide.

Spence R. *Role of exercise in cancer survivorship and evidence-informed exercise recommendations.* Breakfast Symposium Speaker. COSA-IPOS 2025 Annual Scientific Meeting, November 2025, Adelaide.

Spence R. *The role of the MDT in supporting beneficial exercise and diet behaviours.* Breakfast Symposium Co-coordinator. COSA-IPOS 2025 Annual Scientific Meeting, November 2025, Adelaide.

Spence R. *What We Say How It's Heard: Patient-Centred Communication in Cancer.* Invited Speaker. ANZGOG Annual Scientific Meeting, March 2026, Gold Coast.

Spence R. *The 'why, what and how' of supporting people to exercise.* Invited Speaker. Brisbane Cancer Conference, November 2025, Brisbane.

Subba S. *Systematic review of geographical and spatial disparities in incidence and survival of liver cancer across different countries over the last 20 years.* Abstract Presentation. 5th Cancer Council / AEA Cancer SIG ECR Epidemiology Conference, November 2025, Virtual.





Appendix E: Professional and community activities

EXPERT ADVISORY COMMITTEES, SCIENTIFIC PANELS AND WORKING GROUP MEMBERSHIPS

ANZCHOG – Australian New Zealand Children's Haematology Oncology Group

Academic Director for Chinese Anti-Cancer Association Australia

AusEnHealth Stage 2 Steering Committee

Australasian Association of Cancer Registries

Australia Childhood Cancer Registry Advisory Group

Australian Government, Medical Services Advisory Committee Evaluation Subcommittee (ESC) member

Australian Government, Medical Services Advisory Committee (MSAC) member

Australia New Zealand Gynaecological Oncology Group - Member, EDEN Survivorship Group

Australia New Zealand Gynaecological Oncology Group - Research Advisory Committee member

Benchmarking International Childhood Cancer Survival by Toronto Stage (BENCHISTA) Collaborative Project, Project Working Group

Cancer Clinical Trials Advisory Group (CCTAG)

Cancer Council Australia – NAPAC (Nutrition, Alcohol and Physical Activity Committee)

Cancer Council Australia Public Health Committee

Cancer Council Cancer Screening and Immunisation Portfolio group

Cancer Council Cancer Screening and Immunisation Portfolio – Bowel Cancer Screening SIG

Cancer Council Cancer Screening and Immunisation Portfolio – Melanoma Screening SIG

Cancer Council National Skin Cancer Committee

Cancer Council Queensland Cancer Clinical Trials Advisory Group

Cancer Council Queensland Research Advisory Group (RAG)

Cancer Council Research Intelligence Sub-Committee (CCRISC)

Centre of Research Excellence Review panel member

Children's Cancer CoLab Survivorship group

COSA Financial Toxicity Working Group, member

Early Career Network - Leadership Committee

ENCORE Advisory Group member

Equitable Cancer Outcomes across Rural and Remote Australia (ECORRA) Group, Trial Advisory Committee

International Society of Pediatric Oncology, Scientific Committee

Member for the Dietitians Australia Oncology Interest Group Leadership Committee

NHMRC Peer Review of Centre of Research Excellence Grant Panel Member

National Targeted Skin Cancer Screening Roadmap – WORKSTREAM 3 Committee

National Targeted Skin Cancer Screening Roadmap – WORKSTREAM 4 Committee

National Targeted Skin Cancer Screening Roadmap – Expert Advisory Committee

Psycho-oncology Co-operative Research

Group for Cancer Carers Research

Psycho-Oncology Co-Operative Research Group: Screening and Prevention SIG

Skin Cancer Prevention Queensland, Co-Chair

QSkin Committee Working Group

Queensland Collaborative for Cancer Survivorship, Executive Committee Members

Queensland Cooperative Oncology Group, Management Committee

Skin Cancer Prevention Queensland Co-Chair

University of Southern Queensland, Research Committee - School of Psychology and Wellbeing

Victorian Cancer Registry Strategic Advisory Group

CONFERENCE ORGANISING COMMITTEES

Australasian Epidemiology Association and Cancer Council Early Career Researcher Cancer Epidemiology Conference Organising Committee

PROFESSIONAL MEMBERSHIPS

ARMS (Australasian Research Management Society)

Australia New Zealand Gynaecological Oncology Group

Clinical Oncology Society of Australia (COSA)

Exercise and Sports Science Australia

International Agency for Research on Cancer

International Society of Exercise Oncology

International Society of Lymphology

VCCC Alliance Leadership Academy

Australian Health Economics Society
International Health Economics Association
Public Health Association of Australia
REVIEWS AND EDITORIAL ACTIVITIES
Reviews for Journals
Acta Psychologica
Australian and New Zealand Journal of Public Health
BMC Cancer
BMC Complementary Medicine and Therapies
BMC Health Services Research
BMC Palliative Care
BMC Primary Care
BMC Public Health
BMJ Open
British Journal of Cancer
Cancer Causes and Control
Cancer Control
Cancer Epidemiology
Cancer Medicine
Cancers (Basel)
European Journal of Oncology Nursing
European Journal of Paediatrics
Expert Review of Pharmacoeconomics
& Outcomes Research
Frontiers Oncology
Health and Place
Health Expectations

Health Promotion Journal of Australia
International Journal of Cancer
International Journal of Epidemiology
JAMA Oncology
Journal for Lipids in Health and Disease
Journal of Epidemiology and Community Health
Journal of Health Psychology
The Lancet Oncology
Medical Journal of Australia
Palliative Medicine
Patient Education and Counselling
Public Library of Science ONE (PLOS ONE)
Seminars in Oncology Nursing
Scientific Reports
Spatial and Spatio-temporal Epidemiology
Supportive Care in Cancer
Examined theses:
Deakin University
Monash University
The University of Queensland
The University of Sydney





Viertel Cancer
Research Centre

cancerqld.org.au